Advertisement
Canada markets close in 1 hour 44 minutes
  • S&P/TSX

    21,861.10
    -150.62 (-0.68%)
     
  • S&P 500

    5,067.57
    -2.98 (-0.06%)
     
  • DOW

    38,454.56
    -49.13 (-0.13%)
     
  • CAD/USD

    0.7297
    -0.0023 (-0.32%)
     
  • CRUDE OIL

    82.65
    -0.71 (-0.85%)
     
  • Bitcoin CAD

    88,710.73
    -2,818.85 (-3.08%)
     
  • CMC Crypto 200

    1,401.43
    -22.67 (-1.59%)
     
  • GOLD FUTURES

    2,336.30
    -5.80 (-0.25%)
     
  • RUSSELL 2000

    1,995.11
    -7.54 (-0.38%)
     
  • 10-Yr Bond

    4.6560
    +0.0580 (+1.26%)
     
  • NASDAQ

    15,703.97
    +7.33 (+0.05%)
     
  • VOLATILITY

    15.74
    +0.05 (+0.32%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • CAD/EUR

    0.6821
    -0.0015 (-0.22%)
     

Is Ocugen Finally on the Way to Vaccine Revenue?

Is Ocugen Finally on the Way to Vaccine Revenue?

Last year, Ocugen (NASDAQ: OCGN) shares soared more than 700% over just a few days. The company signed an agreement to co-commercialize Bharat Biotech's coronavirus vaccine in the U.S. The companies later added rights in Canada to the agreement too. Bharat's product -- Covaxin -- already had gained emergency authorization in its home country of India.